Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViiV's Dovato Could Challenge Status Quo In Naive EU HIV Patients

Executive Summary

The approval of ViiV’s new once-daily, two-drug single-pill for HIV/AIDS could lead to a tough battle in Europe with established therapies.

You may also be interested in...



Janssen And ViiV: Giving HIV/AIDS Patients Options Is Key

With EU submissions for once-monthly long-acting  anti-HIV antivirals in hand, Janssen and ViiV appear to have set their sights on providing patients with more options.

A Switch To ViiV's Two-Drug Dovato Keeps HIV Suppressed

Top-line results from the Phase III TANGO study suggests that switching to ViiV’s two-drug Dovato from a three-drug regimen does not affect the efficacy of treatment.

GSK Gets A Boost From Shingrix And Other New Drugs

The shingles vaccine Shingrix and new HIV and respiratory drugs drove first quarter growth at GlaxoSmithKline, even as Advair and Breo sales were impacted by a generic.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel